Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1551)	12/4/2003 9:41:03 AM
From: tuck	Read Replies (1) \| Respond to of 1784

>>SAN DIEGO, Dec. 4 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (Nasdaq: DPII - News) announced today that it is strengthening its R&D relationship with Allergan, Inc. (NYSE: AGN - News) by entering into a lead finding collaboration for multiple, unique GPCR and enzyme targets of significance to ophthalmology and neurology therapeutic areas. Financial terms of the collaboration were not disclosed. "We are delighted to be expanding our relationship with Allergan and look forward to bringing our discovery biology resources to bear on these exciting therapeutic targets," stated Taylor Crouch, President and COO for Discovery Partners. "Our current chemistry and biology collaborations are progressing positively and it is gratifying that Allergan has identified DPI as a key drug discovery partner. Our integrated drug discovery capabilities and platforms are an excellent fit with Allergan's capabilities and we look forward to collaborating with them to advance their drug discovery programs." "Discovery Partners' technologies enabling lead identification complement our internal efforts. We continue to have a fruitful collaboration with DPI in several areas," stated Lester Kaplan, Ph.D., Executive Vice President and President, Research and Development for Allergan.<< snip Cheers, Tuck